News

Celeris Therapeutics Welcomes Dr. John Harling, a Pioneer in PROTACs and TPD, as Chair of its Scientific Advisory Board

EINPressWire – January 12, 2024

Celeris Therapeutics, a trailblazer in AI-driven drug discovery, is elated to announce the appointment of Dr. John Harling as the Chair of its Scientific Advisory Board. 

Celeris Therapeutics Appoints James Field as Board Director, Bringing Expertise in TechBio Scaling, Robotics, and AI

EINPressWire – September 15, 2023

 Celeris Therapeutics, a pioneering therapeutics company, announces the appointment of Dr. James Field as Board Director

Dr. Chris Tame Joins Celeris Therapeutics as VP, Head of Drug Discovery

EINPressWire – September 04, 2023

 Celeris Therapeutics, a pioneering therapeutics company, announces the appointment of Dr. Chris Tame as the Vice President, Head of Drug Discovery.

Celeris Therapeutics to receive 12.5 million Euros in funding from the European Innovation Council

EINPressWire – October 19, 2022

Celeris Therapeutics, the pioneer in AI-driven degrader design, today announces funding from the European Innovation Council (EIC).

CelerisTx Announces Key Management Promotion

EINPressWire – June 14, 2022

Celeris Therapeutics, Inc., the pioneer in AI-driven proximity-inducing compound (PIC) design, today announced the promotion of Dr. Markus Muellner to Chief Scientific Officer.

CelerisTx Reels in Another Big Partner in Boehringer Ingelheim

BioSpace® – April 05, 2022

Celeris Therapeutics and Boehringer Ingelheim (BI) have announced they are entering into a collaboration to develop next-generation targeted protein degraders.

CelerisTx Appoints Pharmaceuticals Industry Leader Peter Ho, M.D., Ph.D., to the Board of Directors

BioSpace® – February 25, 2022

CelerisTx, the pioneer in AI-driven proximity-inducing compound discovery, today announced the appointment of Peter T.C. Ho, M.D., Ph.D., to the Board of Directors.

CelerisTx announces $4.4m financing to advance pipeline of novel proximity inducing compound

BioSpace® – February 10, 2022

Celeris Therapeutics, the PIC™ engineering company, announces the closing of their $4.4m USD Series Seed Financing round.

Merck KGaA enlists little AI player on protein degrader discovery

Endpts – February 09, 2022

The German pharma has tapped CelerisTx, a Menlo Park, CA-based biotech with roots in Austria, and its artificial intelligence platform for two drug discovery projects. The main goal, according to the companies, is to identify active small molecule binders.

CelerisTx in Artificial Intelligence research collaboration with Merck KGaA, Darmstadt, Germany on AI-enabled degrader discovery

BioSpace® – February 09, 2022

Collaboration enables Merck KGaA, Darmstadt, Germany access to CelerisTx AI platform across two drug discovery projects

Celeris Therapeutics, the PIC™ engineering company, announces the appointment of biotech veterans to lead drug discovery and biology efforts

BioSpace® – February 02, 2022

The hirings of Dr. Friedrich Kroll, who is joining as VP Drug Discovery, and Dr. Markus Muellner joining as VP Biology, reflect the ambition to get into the clinic fast.

Celeris Therapeutics, Inc., pioneering AI-driven degrader discovery, appoints Nick DeHaan as VP, Head of Partnering

EINPresswire – November 29, 2021

Silicon Valley-based startup recruits experienced business development leader to drive growth in AI-based protein degrader discovery partnerships

Celeris Therapeutics, the Pioneer in AI-driven Degrader Design, Builds Laboratories in Austria

EINPresswire – November 01, 2021

Adds ~25 new jobs, building on 20 created in 2021. Increases capacity and efficiency of AI-based drug discovery capabilities in chemistry and biology.

The Third Wave of Degrader Discovery

Christopher Trummer – October 25, 2021

The Third Wave of Degrader Discovery Proteins occupy a special place in the biological domain as the master regulators of biochemical processes in the cell. They accomplish this as enzymes, hormones, transporters, signal transducers, and other complex molecules to ensure the cell maintains a homeostatic balance. This system, while amazingly resilient, breaks down when those […]

Webinar: Machine Learning meets Degrader Design

Arjun Rao – September 23, 2021

Celeris Therapeutics Welcomes Life Sciences and Technology Thought Leader Ian Marks as a Non-Executive Director

EINPresswire – August 27, 2021

Global VP of Life Sciences at Salesforce contributes a great deal of experience in life sciences, pharma and technology

Rational design for protein degradation? Austrian deep learning startup takes a stab

Endpoints – July 19, 2021

Rational design for protein degradation? Austrian deep learning startup takes a stab

600.000 Euro für Grazer Startup Celeris

Der Brutkasten – May 3, 2021

Knapp nach einem 400.000 Euro Seed-Investment holt sich Celeris aus Graz eine aws-Förderung für seine Medikamentenforschungstechnologie.

Cutting longevity drugs development from 15 years to on

Noah Weber – March 31, 2021

Celeris bags €400k for creation of deep learning platform to support development of longevity drugs for Alzheimer’s and other age-related diseases.

Accelerating drug discovery through artificial intelligence would help to bring longevity innovations to the clinic more quickly.

Lifespan.io – April 06, 2021

We all know that technology is rapidly improving and changing how we live. But we’re going to need even more technological breakthroughs to improve human maximum healthspan and lifespan. Can a new start-up cut longevity drugs development from 15 years to one?

Grazer Biotech-Startup erhält 400.000 Euro Pre-Seed-Investment

Der Brutkasten – March 31, 2021

Celeris Therapeutics will mit seiner Plattform ermöglichen, dass bessere Medikamente schneller auf den Markt kommen – und konnte damit internationale Investoren überzeugen.

Durch künstliche Intelligenz zum perfekten Medikament

CHEManager – January 26, 2021

Eine Deep-Learning-Plattform für medizinische Chemiker zur schnelleren und genaueren Vorhersage von Bindungsaffinitäten und daraus resultierendem Design von Arzneimitteln – das will das Start-up Celeris Therapeutics aus Graz noch dieses Jahr zur Marktreife entwickeln.